Dysport: AbobotulinumtoxinA by Ipsen for Aesthetic Wrinkle Treatment
Overview: Dysport (AbobotulinumtoxinA)
Dysport is the therapeutic trade name for AbobotulinumtoxinA from Swiss pharmaceutical company Galderma, used for medical (therapeutic) indications. The aesthetic version of the identical product is marketed as Vistabel in Europe. Dysport is one of the oldest botulinum toxin preparations on the market, with a long history of use in neurology, ophthalmology, and rehabilitation medicine before its application in aesthetic medicine became prominent.
AbobotulinumtoxinA (Dysport/Vistabel) differs from OnabotulinumtoxinA (Botox) in its formulation, protein content, and diffusion properties. The dosage units are not interchangeable (approximately 2.5 to 3 Dysport units correspond to 1 Botox unit). Dysport has a slightly greater diffusion radius than Botox, which can be advantageous in some indications (e.g., treating large muscle areas) and disadvantageous in others (precision injections near sensitive structures).
Mechanism of Action
Like all botulinum toxin preparations, Dysport works by blocking neuromuscular transmission. AbobotulinumtoxinA irreversibly cleaves the SNAP-25 protein at the presynaptic terminal, preventing the fusion of acetylcholine vesicles with the membrane and thereby inhibiting acetylcholine release. Without acetylcholine, the muscle cannot contract, leading to a localized, reversible muscle paralysis. The effect is temporary because new nerve terminals grow around the blocked junction (axonal sprouting) and new SNAP-25 protein is synthesized.
Therapeutic Indications
Neurology: Spasticity in adults (post-stroke, multiple sclerosis, cerebral palsy) and children (cerebral palsy, lower limb spasticity), cervical dystonia (torticollis), blepharospasm (involuntary eyelid closure), hemifacial spasm.
Rehabilitation: Focal spasticity after stroke for improved function and pain reduction; equinus foot in pediatric cerebral palsy patients.
Ophthalmology: Strabismus (misalignment of eyes), nystagmus.
Urology/Gastroenterology: Overactive bladder, anal fissure.
Aesthetic Application (as Vistabel)
Approved aesthetic indication in Europe: Temporary improvement of moderate to severe glabellar lines. Commonly used off-label (as Vistabel): forehead lines, crow's feet, brow lifting, platysma bands, hyperhidrosis, bruxism, and gummy smile. The aesthetic dose is significantly lower than therapeutic doses used for spasticity.
Treatment
Therapeutic Dysport injections are performed by specialized physicians (neurologists, physiatrists, ophthalmologists). Injection is guided by EMG, ultrasound, or anatomical landmarks. Dosage varies widely depending on indication (30 to 1,000+ units). Treatment intervals: every 3 to 6 months for most indications. Aesthetic Vistabel treatment: 10 to 20 minutes outpatient.
Safety
Dysport is an approved drug with decades of clinical experience across multiple indications. Common side effects vary by indication: for aesthetic use — headache, mild bruising, temporary redness; for spasticity treatment — muscle weakness in adjacent muscles, dysphagia (if neck muscles involved). Contraindications: myasthenia gravis, Lambert-Eaton syndrome, aminoglycoside antibiotics, pregnancy, breastfeeding. Prescription-only.
Costs
Therapeutic Dysport treatments (spasticity, cervical dystonia) are covered by health insurance in most European countries. Aesthetic Vistabel treatments: €200 to €500 for glabellar lines; €400 to €800 for three areas. Not covered by insurance for aesthetic indications.